Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262

Fink, A. M., Maurer, C., Bahlo, J., Kluth, S., Linde, H., Aldaoud, A., Illmer, T., Dengler, J., Klausmann, M., Lathan, B., Al-Sawaf, O., Fischer, K., Wendtner, C. -M, Eichhorst, B. and Hallek, M. (2016). Three years after the start of enrolment: Current data from the prospective CLL-registry of the German CLL Study Group. Oncol. Res. Treat., 39. S. 256 - 257. BASEL: KARGER. ISSN 2296-5262

Kovacs, G., Bahlo, J., Kluth, S., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Gross-Opphoff-Mueller, C., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Hallek, M., Eichhorst, B. and Goede, V. (2015). Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A. -M, von Bergwelt-Baildon, M., Hallek, M., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Impact of antibiotic treatment modulating the intestinal microbiota on the efficacy of antineoplastic treatment for chronic lymphatic leukaemia or relapsed lymphoma. Oncol. Res. Treat., 38. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262

Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

This list was generated on Sun Mar 26 04:49:34 2023 CEST.